logo.jpg (2912 bytes)

health_banner.jpg


     

July-Aug & Sept-Oct 2002
download.gif (450 bytes)

news_home.jpg
editorial1.gif
lead_story.jpg
briefs.jpg
book_review.jpg
campaign.jpg
letters.jpg
news_arcive.jpg
writetous.jpg
health_home.jpg
cse_home.jpg

join.gif
If you are interested in receiving the copy of the newsletter, do write to us. Join our nework.

 

lead_story1.jpg (1699 bytes)

Bringing about change
Counterfeit drugs today form a part of an organised crime. Corruption, business interests of unscrupulous politicians and unregulated pharmaceutical companies have led to the increase in this trade. To combat the incidence of counterfeit and substandard drugs, the governments need to strengthen their drug regulatory authorities and their powers to enforce drug laws and regulations. Every step in the counterfeiting of drugs, from the manufacture, import, export, distribution, and sale of counterfeit and substandard drugs should be prohibited by law as a serious criminal offence. The government should re-work the existing law and ensure that the offence is no longer a minor offence confined to the state drug controller suspending or cancelling the licences of medicine shops selling spurious drugs.

Drug registration in India needs to be strengthened to ensure that all drugs that are, domestically produced as well as those imported are assessed for safety, efficacy, and quality before they are available to the consumers. To achieve this, drug regulatory authorities should develop significant capacity and know-how. Political pressures prevent drug inspectors from investigating counterfeit and substandard drugs and prosecuting counterfeiters. Inspectors should be given the rights to enter manufacturing or packaging premises collect samples for tests, and not conduct sale of the drugs until they check the results of the tests.

Having sophisticated tools for investigating counterfeit medicines is required if any progress is to be made in curbing the menace of spurious drugs. The use of near-infrared spectroscopy (NIRS) for rapid, on-site and non-destructive identification of counterfeit pharmaceuticals has been well documented.21 Upgradation of testing laboratories and training of scientific personnel in these laboratories for quick analysis of drug samples and the setting up of special courts to deal with summary trials would help control the entry of spurious and substandard drugs in the supply chain.

New committe


With a view to achieve better integration between the health policies and the industrial policies in the Pharmaceutical sector, the Drug Controller Authority of India proposes the setting up of an inter-ministerial Standing Committee. The committee will constitute the Ministry of Industry, Department of Chemicals and Petrochemicals with the Ministry of Health and Family Welfare and officials of the other departments like Bureau of Industrial Costs and Prices, Biotechnology, and Ministries of Commerce and Revenue as members. The Committee would oversee the following:

  • implementation of new measures and other related decisions such as revision of the National Formulary which would undertake scientific scrutiny of master formulae for manufacture of formulations

  • strengthening of the institutional and statutory arrangements for enforcing quality control

  • dissemination of information regarding safety and efficacy of drugs to medical and paramedical personnel

  • centralisation of drug registration, rationalisation of formulations and monitoring of adverse effects of drugs.

Organisation of Pharmaceutical Producers of India (OPPI) along with the IFPMA and the Pharmaceutical Security Institute (Geneva, Switzerland) is planning to set up an intelligence network to counter the counterfeit drugs trade. Glaxo is going in for holograms, special ink, printed/locked capsules, biocodes and embossing of tablets with a logo, explains P S Khanna, resident director of OPPI in Delhi. Many are also seeking the help of private detective agencies or using marketing staff to monitor the trade.

Major Indian pharmaceutical companies — Alembic, Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy, Sun Pharmaceutical and Wockhardt have joined hands to form the Indian Pharmaceutical Alliance (IPA) to look into the counterfeit trade. Their anti-piracy task force looks especially into complaints regarding counterfeit drugs.22 The setting up of an inter-ministerial Standing Committee would also help check this burgeoning trade (see box: New committee).23

India's reputation as the hub of counterfeit drug exports may have a serious consequence to the industry in the future. The current practice of large industries contracting with small-scale units for smaller "jobs" indicates the limited capacity of the producers resulting into poor quality of the drug. Additionally, with no recall policy in the pharmaceutical sector, the drugs with expired data of use would persist in the market until they are bought out. Small-scale units that undertake production on a contractual basis from the large scale companies are more than willing to produce large quantities of medicines especially due to the insecurity business, and thereby their income.

Internally, DCA and pharma companies should monitor the movement of every batch of every drug. A chain of command that is monitored by the pharma company and strong punitive measures by DCA will ensure that fake drug markets are stamped out. A recent Supreme Court hearing in the case of Venu Veterinary Division, has ruled that a dealer in drugs and cosmetics could be prosecuted for selling spurious or substandard goods. This important hearing sets the distributor and manufacturer apart, with the Supreme Court stating that there is no prohibition in the law which states that a dealer cannot be prosecuted for sale of spurious medicines or cosmetics below the prescribed standard of quality without the manufacturer also being made a co-accused.24 What is needed is more stringent laws like this to deal with the burgeoning counterfeit mafia trade.

Government is contemplating tightening the law against spurious drugs flooding the market and may bring a bill to amend the provisions of the existing laws for the purpose. "Law is there but it is not adequate. We must strengthen the law as spurious drug manufacturers are the real killers and antinationals, "Health Minister Shatrughan Sinha said. However, there are certain drawbacks in the existing law. If spurious drugs are caught, the onus to prove that the medicine did not belong to them lies with the manufacturers of genuine medicines," Sinha said.

One way to track the prevalence of counterfeit drugs is to define the points of entry of drugs into the market. Rigorous inspection and surveillance should be conducted in collaboration with customs and police to prevent and control smuggling. South Asian and Indian ports are notorious for exporting spurious drugs to Africa, Russia and South East Asia. Custom officials are not trained to distinguish between drugs, and therefore are incapable to prevent smuggling of counterfeit drugs. Combating counterfeit and substandard drugs at the national level is thus a shared responsibility involving the relevant government agencies, pharmaceutical manufacturers, distributors, health professionals, and the general public. Making them realise how their interests are threatened would help focusing their attention on the issue.

 

References

1. R C Miller, 1998, Growing Gray Economies, The Rand Review, The RAND Corporation, Arlington, Virginia, USA.

2. Essential drugs and medicines policy, World Health Organisation, www.who.int/medicines/organization/ qsm/activities/qualityassurance/counterfeit/counterfeit_info-facts.shtml.

3. R D Srivastava 2002, Fake drugs thrive in city marts, article in Hindustan Times, February 20, New Delhi.

4. www.expresshealthcaremgmt.com/20021115/ insignia2.htm

5. P Chatterjee 2001, India's trade in fake drugs-bringing the counterfeiters to hook, in The Lancet, Vol 357, No 9270, June 2.

6. Jagvir Singh et al 2000, Diethylene glycol poisoning in Gurgaon, India, 1998, Bulletin of the World Health Organisation, World Health Organisation, Geneva, Vol 79, No 2, p 8895.

7. S Jha 2002, Spurious drug kingpin still has a licence, article in The Times of India, Patna edition, October 5.

8. Emma Wilkinson 2002, Murder by fake drugs, editorial in The British Medical Journal, Vol 324, April, pp 800-801.

9. Toye Olori 2002, Major combat to fight fake drugs, Inter Press Service, July 30.

10. P Newton et al 2001, Fake artesunate in Southeast Asia, in The Lancet, Vol 357, No 9272, June 16, pp 1948-1950.

11. Business week 2001, What's in that pill, www.businessweek.com/magazine/content/2001_25/b3737153.htm, June 18.

12. AIPM 2001, Taxing medicine: a bad prescription for russian consumers. A fact Sheet on the RF Government’s Proposed Imposition of a Value-Added Tax on Pharmaceuticals and Other Medical Products, Association of International Pharmaceutical Manufacturers, October.

13. US Senate Special Committee on Aging, Hearing on "Buyer Beware: Public Health Concerns Of Counterfeit Medicines" 2002, Transcript prepared by Pharmaceutical Research and Manufacturers of America, Washington D.C. July 9.

14. Anon 2002, Spurious drug racket busted, article in Criminal Intelligence Digest, http://cbi.nic.in/ fsep.htm.

15. Eshetu Wopndemagegnehu 1999, Counterfeit and Substandard Drugs in Myanmar and Vietnam –Report of a study carried out in cooperation with the Governments of Myanmar and Vietnam, World Health Organisation, Essential Drugs and Other Medicines, Geneva.

16. Toye Olori 2002, Major combat to fight fake drugs, Inter Press Service, July 30.

17. Ori Twersky, Counterfeit drug creep into nation’s drug supply, http://my.webmd.com/content/article/ 1728.58312, as viewed on September 25, 2002.

18. C Kapp 2002, Counterfeit drug problem "underestimated", says conference, article in The Lancet, Vol 360, No 9339, October 5, p 1080.

19. International Federation of Pharmaceutical Manufacturers Association, 1997, February.

20 www.pharmafile.com/pharmafocus/Features/ feature.asp?fID=162&m=12

21. S H Scafi and C Pasquini 2001, Identification of counterfeit drugs using near-infrared spectroscopy, in Analyst, Vol 126, No 12, December, pp 2218-2224.

22. S Asthana 1999, Eight drug firms come together, float association, article in the Financial Express, November 26.

23. Modifications in drug policy 1986, www.medindia.net/ buy_n_sell/pharm_industry/ph_drugpolicy.asp

24. Anon 2002, Dealers of spurious drugs can be prosecuted, article in Business Standard, October 28.

 

Next Page Next Page | Bringing about change 1 2 3 4 5 6 7
past.gif (491 bytes)  
 
CHILDREN AT RISK   ASTHMA   POVERTY, HEALTH AND ENVIRONMENT

email.gif